Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
What To Do To Fix Your Budget presents a practical plan to reduce waste and stabilize spending.
16,879 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Is Pfizer stock undervalued in the crowded healthcare space? This deep dive weighs cash flow, dividends, pipeline pot...
A Gartner forecast signals a seismic shift: 40% of enterprise apps will embed AI agents by 2026. This article breaks ...
A major partnership reshapes Novo Nordisk's growth trajectory. This deep dive explains what the Vivtex deal means for...
Navitas Semiconductor shares moved sharply higher as investors weighed strong earnings against exciting long-term gro...
In 2026, SoFi's private student loans and refinancing options face a competitive market and shifting rates. This sofi...
MercadoLibre's fourth-quarter results showed strong revenue growth, but a notable drop in profitability. This article...
Investors are expanding beyond Vanguard in March 2026 as cost, access, and tool diversity drive choice. This report h...
Oracle stunned traders with a solid earnings beat and optimistic long-term guidance, fueling a surge in after-hours a...
When a leading shipping stock leaps by a double-digit percentage, traders watch closely for what's driving the gains....
A larger stock buyback authorization sent BlackLine's shares higher, signaling confidence from management. This analy...
Growth stocks cooled in early 2026, but a trio of ETFs offers a resilient path for long-term investors. This piece br...